News

Scancell is developing SCIB1 for the treatment of cancer and infectious diseases based on its ImmunoBody technology platform. The trial, which was started in June 2010, is intended

In the study Zohydro showed improved chronic pain relief in comparison to placebo. Additionally, the study also met the two secondary endpoints, specifically, the proportion of patients with

The plant offers capacity and capability for the manufacture of several solid dosage forms. In addition to standard manufacturing capabilities, the facility offers advanced tablet production: bi-layer, tri-layer,

With this, the original deal signed in December 2005 has been extended thrice and it now covers a range of drug discovery programs. The programs use Argenta’s expertise

Endo Pharma has originally signed the deal in February 2009, under which Grunenthal has given axomadol development and marketing rights Endo in the US and Canada. The results

Developed under the collaboration with Abbott, TRU-016 is a CD37-directed Small Modular ImmunoPharmaceutical protein therapeutic in development as a treatment for B-cell malignancies. The company expects to recruit

The development was done to avoid problems caused by increasing data volumes and this system will be made available across Bio-Rad’s European sites in Germany, Italy and the

The resubmission was done following the issuing of complete response letter (CRL) by the FDA in February 2011. Taliglucerase alfa is Pfizer‘s proprietary plant cell expressed recombinant form

Crizotinib is indicated as a treatment for patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC). Bosutinib is indicated as a treatment for patients with newly